Table 4. Univariate and multivariate analysis of prognostic factors for overall survival in 50 HCC patients after living donor liver transplantation.
| Factors | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Recipient age | 1.04 (0.97–1.12) | 0.244 | – | – | |
| Recipient BMI >25 kg/m2 | 0.38 (0.09–1.70) | 0.204 | – | – | |
| Progressive hyperbilirubinemia | 2.85 (0.64–12.69) | 0.169 | – | – | |
| Refractory ascites | 1.47 (0.42–5.23) | 0.548 | – | – | |
| MELD score >20 | 2.85 (0.64–12.69) | 0.169 | – | – | |
| Child-Pugh classification C | 1.38 (0.51–3.71) | 0.523 | – | – | |
| Portal vein thrombosis | 1.79 (0.50–6.34) | 0.368 | – | – | |
| Pretransplant infection | 0.97 (0.13–7.35) | 0.972 | – | – | |
| Sarcopenia | 2.75 (0.95–7.97) | 0.062 | 2.49 (0.85–7.14) | 0.095 | |
| Pretransplant hospital stay | 1.93 (0.70–5.34) | 0.204 | – | – | |
| Operative time >10 hours | 0.58 (0.21–1.60) | 0.290 | – | – | |
| Meeting Milan criteria | 0.29 (0.10–0.92) | 0.035 | 0.31 (0.10–1.00) | 0.051 | |
| Tumor size | 1.11 (0.97–1.26) | 0.119 | – | – | |
| Tumor number | 1.07 (0.90–1.27) | 0.440 | – | – | |
| AFP >400 ng/mL | 1.12 (0.38–3.23) | 0.836 | – | – | |
| Donor BMI | 0.96 (0.81–1.15) | 0.691 | – | – | |
| GRWR >0.8% | 0.41 (0.12–1.47) | 0.172 | – | – | |
| ABO incompatible | 1.27 (0.44–3.67) | 0.659 | – | – | |
| Biological related donor | 0.88 (0.25–3.10) | 0.841 | – | – | |
HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval; BMI, body mass index; MELD, model for end-stage liver disease score; AFP, alpha fetoprotein; GRWR, graft-to-recipient weight ratio; HR, hazard ratio.